NCT05042310

A Study of LY3541860 in Healthy Japanese and Non-Japanese Participants

A Phase 1, Randomized, Participant- and Investigator-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3541860 in Healthy Japanese and Non-Japanese Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 94 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 20 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3541860 in healthy Japanese and non-Japanese participants. The study will also assess how fast LY3541860 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 113 days.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY3541860	Administered either IV or SC.
DRUG	Placebo	Administered either IV or SC.

Timeline

• Start date: 2021-11-11
• Primary completion: 2023-12-27
• Completion: 2023-12-27
• First posted: 2021-09-13
• Last updated: 2024-04-05

Locations

1 site across 1 country: Japan